Optimal Detection of Latent Mycobacterium tuberculosis Infection by Combined Heparin-Binding Hemagglutinin (HBHA) and Early Secreted Antigenic Target 6 (ESAT-6) Whole-Blood Interferon Gamma Release Assays.

early secreted antigenic target 6 heparin-binding hemagglutinin interferon gamma release assay latent tuberculosis infection whole blood

Journal

Journal of clinical microbiology
ISSN: 1098-660X
Titre abrégé: J Clin Microbiol
Pays: United States
ID NLM: 7505564

Informations de publication

Date de publication:
18 05 2022
Historique:
pubmed: 19 4 2022
medline: 21 5 2022
entrez: 18 4 2022
Statut: ppublish

Résumé

Optimal detection of latent tuberculosis (TB) infection (LTBI) remains a challenge, although it is essential to reach the goal of TB elimination. Our objective was to develop and clinically evaluate a user-friendly, 24-h, whole-blood (WB) interferon gamma (IFN-γ) release assay (IGRA) improving the detection of LTBI, compared to available tests. One milliliter of blood was divided into four aliquots and

Identifiants

pubmed: 35430897
doi: 10.1128/jcm.02443-21
pmc: PMC9116186
doi:

Substances chimiques

Antigens, Bacterial 0
Lectins 0
heparin-binding hemagglutinin 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0244321

Subventions

Organisme : Tuberculosis Vaccine Initiative
ID : NORAD
Organisme : INNOV-IRIS Brussels
Organisme : European Commission (EC)
ID : HEALTH-2009-2.3.2-2
Organisme : Fonds De La Recherche Scientifique - FNRS (FNRS)
ID : PDR T.0147.13

Références

J Immunol. 2018 Nov 1;201(9):2541-2548
pubmed: 30348659
J Clin Microbiol. 2020 Aug 24;58(9):
pubmed: 32493779
Tuberculosis (Edinb). 2017 Sep;106:62-72
pubmed: 28802407
Int J Infect Dis. 2020 Feb;91:177-181
pubmed: 31877486
Nat Med. 2004 Sep;10(9):935-41
pubmed: 15300244
Adv Med Sci. 2019 Sep;64(2):437-443
pubmed: 31586819
PLoS One. 2007 Oct 03;2(10):e926
pubmed: 17912342
PLoS One. 2011 Mar 29;6(3):e18315
pubmed: 21479248
Eur Respir J. 2009 May;33(5):956-73
pubmed: 19407047
Lancet Infect Dis. 2017 Oct;17(10):e327-e333
pubmed: 28495525
Tuberculosis (Edinb). 2018 Jan;108:136-142
pubmed: 29523314
Clin Vaccine Immunol. 2007 Jul;14(7):880-5
pubmed: 17507543
PLoS One. 2012;7(8):e43285
pubmed: 22912846
Infect Immun. 2006 May;74(5):3006-11
pubmed: 16622240
Am J Respir Crit Care Med. 2017 Sep 1;196(5):638-648
pubmed: 28737960
Nat Rev Immunol. 2018 Sep;18(9):575-589
pubmed: 29895826
Clin Vaccine Immunol. 2014 Mar;21(3):321-8
pubmed: 24391135
Lancet Infect Dis. 2018 Oct;18(10):1077-1087
pubmed: 30174209
BMC Nephrol. 2020 Jun 4;21(1):214
pubmed: 32498706
J Infect. 2018 Dec;77(6):526-533
pubmed: 30267797
PLoS One. 2021 Jul 16;16(7):e0254571
pubmed: 34270559
Expert Rev Vaccines. 2015;14(12):1573-85
pubmed: 26517361
Eur J Clin Microbiol Infect Dis. 2017 Aug;36(8):1415-1423
pubmed: 28429162
J Clin Invest. 2021 Feb 1;131(3):
pubmed: 33529162
Curr Med Chem. 2019;26(11):2051-2060
pubmed: 30378481
J Microbiol. 2016 Aug;54(8):565-72
pubmed: 27480637
Am J Respir Crit Care Med. 2007 Aug 15;176(4):409-16
pubmed: 17541018
PLoS One. 2017 Nov 28;12(11):e0188631
pubmed: 29182688
BMC Infect Dis. 2009 Nov 21;9:182
pubmed: 19930588

Auteurs

V Dirix (V)

Laboratory of Vaccinology and Mucosal Immunity, Université Libre de Bruxellesgrid.4989.c, Brussels, Belgium.

N Dauby (N)

Department of Infectious Diseases, Centre Hospitalier Universitaire Saint-Pierre, Université Libre de Bruxellesgrid.4989.c, Brussels, Belgium.
Institute for Medical Immunology, Université Libre de Bruxellesgrid.4989.c, Brussels, Belgium.

M Hites (M)

Department of Infectious and Tropical Diseases, Hôpital Erasme, Université Libre de Bruxellesgrid.4989.c, Brussels, Belgium.

E Watelet (E)

Department of Pneumology, Clinique St. Anne/St. Remi-CHIREC, Brussels, Belgium.

A Van Praet (A)

Laboratory of Vaccinology and Mucosal Immunity, Université Libre de Bruxellesgrid.4989.c, Brussels, Belgium.

A Godefroid (A)

Laboratory of Vaccinology and Mucosal Immunity, Université Libre de Bruxellesgrid.4989.c, Brussels, Belgium.

E Petit (E)

Université de Lille, CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, U-1019, UMR8204, Center for Infection and Immunity of Lille, Lille, France.

M Singh (M)

Lionex Diagnostics and Therapeutics, Braunschweig, Germany.

C Locht (C)

Université de Lille, CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, U-1019, UMR8204, Center for Infection and Immunity of Lille, Lille, France.

F Mascart (F)

Laboratory of Vaccinology and Mucosal Immunity, Université Libre de Bruxellesgrid.4989.c, Brussels, Belgium.

V Corbière (V)

Laboratory of Vaccinology and Mucosal Immunity, Université Libre de Bruxellesgrid.4989.c, Brussels, Belgium.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH